Clinical Trials
138 trialsLUPARPED
Fundación de investigación HM
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
Alliance for Clinical Trials in Oncology
MOMENTUM-1
RTOG Foundation, Inc.
RYZ101 for the Treatment of Progressive or Recurrent Intracranial Meningioma
Ohio State University Comprehensive Cancer Center
NEURO-SUTURE
Medical University of Warsaw
SRS-AIM
University of California, San Francisco
Cabozantinib for Patients With Recurrent or Progressive Meningioma
Baptist Health South Florida
MIRAGE
Istituto Oncologico Veneto IRCCS
Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery
NRG Oncology
INTUITT-NF2
Massachusetts General Hospital
EViDENCE-BT
University of Zurich
NK Cell Therapy for Malignant Solid Brain Tumors
Peking University Third Hospital
Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
Mayo Clinic
A Trial of Increased Dose Intensity Modulated Proton Therapy (IMPT) for High-Grade Meningiomas
Massachusetts General Hospital
Stereotactic Radiosurgery and Immunotherapy (Pembrolizumab) for the Treatment of Recurrent Meningioma
University of California, San Francisco
Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors
Nationwide Children's Hospital
Pilot Study Evaluating Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Intracranial Lesions During Neurosurgical Procedures
Vanderbilt-Ingram Cancer Center
Abemaciclib in Newly Diagnosed Meningioma Patients
St. Joseph's Hospital and Medical Center, Phoenix
Phase II Study of 177Lu-DOTATATE Radionuclide in Adults With Progressive or High-risk Meningioma
NYU Langone Health
MOLI
University Hospital Heidelberg
Ribociclib (LEE011) in Preoperative Glioma and Meningioma Patients
St. Joseph's Hospital and Medical Center, Phoenix
Direct Comparison of Ga-68-DOTATATE and Ga-68-DOTATOC
Weill Medical College of Cornell University
Feasibility of Intraoperative Tracing of Meningioma Using [Cu64]DOTATATE
Weill Medical College of Cornell University
PIVIM
Hospices Civils de Lyon
SIMPLIF-AI
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
HiPPI
Emory University
MRE Evaluation for Spinal Cord Tumor Surgery: Stiffness and Adhesion Assessment
Shengjing Hospital
3D MRE-Based Evaluation of Meningioma Mechanical Properties and Histological Features
Shengjing Hospital
Post-Operative Dosing of Dexamethasone in Patients With Brain Tumors After a Craniotomy, PODS Trial
Emory University
DEX-NEURO
University of Malaya
BIOLIMEN-1
University Hospital, Montpellier
Evaluation of the CONVIVO System
Dartmouth-Hitchcock Medical Center
Zr-89 Crefmirlimab Berdoxam and Immuno-Positron Emission Tomography for the Imaging of Patients With Resectable Brain Tumors
Jonsson Comprehensive Cancer Center
Phase II Trial of Pembrolizumab in Recurrent or Residual High Grade Meningioma
Massachusetts General Hospital
An Open-Label Phase II Study of Nivolumab or Nivolumab/Ipilimumab in Adult Participants With Progessive/ Recurrent Meningioma
Dana-Farber Cancer Institute
A Study of ONC201 for Refractory Meningioma
University of Nebraska
68Ga-Dotatate PET and MRI Guided Radiation Dose Escalation for High Risk Meningioma
Thomas Jefferson University
Exploratory Evaluation of AR-42 Histone Deacetylase Inhibitor in the Treatment of Vestibular Schwannoma and Meningioma
Massachusetts Eye and Ear Infirmary
DOMINO-START
Weill Medical College of Cornell University
HOBSCOTCH-CA
Dartmouth-Hitchcock Medical Center
Molecular-Guided Therapy for Childhood Cancer
Milton S. Hershey Medical Center
CBT-I in PBT
Virginia Commonwealth University
PRIDE
Tata Memorial Centre
γδ T-PD-1 Ab Cells in the Treatment of Malignant Meningioma
Nanjing Medical University
Abemaciclib (LY2835219) in Patients With Recurrent Primary Brain Tumors
Memorial Sloan Kettering Cancer Center
A Dual-targeting Tracer TATE-RGD for the Diagnosis of SSTR- and RGD- Positive Tumors
Peking Union Medical College Hospital
Pilot Study of Optune (NovoTTF-100A) for Recurrent Atypical and Anaplastic Meningioma
Memorial Sloan Kettering Cancer Center
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
Northwestern University
CANCER-COG
Centre Francois Baclesse
Fluorescence Detection of Adult Primary Central Nervous System Tumors With Tozuleristide and the Canvas System
Cedars-Sinai Medical Center